10-Q: Regen Biopharma Faces Critical Cash Shortage, Mounting Losses

Regen Biopharma reported a significant increase in net loss and a critically low cash balance, raising substantial doubt about its ability to continue as a going concern.

Summary

• Regen Biopharma, Inc. incurred a net loss of $967,853 for the quarter ended December 31, 2025, a substantial increase from $515,384 in the prior year's quarter.
• The company's cash balance plummeted to $4,578 as of December 31, 2025, down from $69,555 on September 30, 2025.
• Operating expenses surged to $610,689 for the quarter, primarily driven by $210,000 in Research and Development and $231,925 in General and Administrative expenses.
• The working capital deficit increased by $291,814 to approximately $6.5 million as of December 31, 2025.
• An accumulated deficit of $22,659,473 was reported as of December 31, 2025.
• Management explicitly stated significant doubt about the company's ability to continue as a going concern without additional funding.
• The company issued a substantial number of common shares for cash, debt satisfaction, and compensation, leading to significant dilution.
• Disclosure controls and procedures were deemed ineffective by the Principal Executive Officer and Principal Financial Officer.

Sentiment

Score: 1

Explanation: StockSavvy.ai views this as extremely negative due to the severe 'going concern' warning, critically low cash, escalating losses, and heavy reliance on dilutive financing, indicating significant financial distress and operational instability.

Positives

• The company initiated a planned Phase I Clinical Trial for HemaXellerate, indicating active product development.
• Increased Research and Development spending to $210,000 for the quarter, demonstrating investment in its pipeline.
• Successfully raised capital through the issuance of common stock for cash and conversion of debt, providing some financing.
• Rent expense decreased due to the termination of a sublease and the use of office space provided by the CEO free of charge.

Negatives

• Net loss significantly increased to $967,853 for the quarter ended December 31, 2025, compared to $515,384 for the same period in 2024.
• Operating loss dramatically worsened to $551,624 from $61,378 year-over-year.
• Cash balance is critically low at $4,578 as of December 31, 2025, a sharp decline from $69,555 at September 30, 2025.
• Working capital deficit expanded to approximately $6.5 million, indicating severe liquidity issues.
• Accumulated deficit reached $22,659,473, reflecting sustained unprofitability.
• General and Administrative expenses and Research and Development expenses saw substantial increases.
• Disclosure controls and procedures were deemed ineffective by management.
• Heavy reliance on dilutive equity financing and convertible debt continues to increase the derivative liability to $2,460,443.

Risks

• Significant doubt exists regarding the company's ability to continue as a going concern due to recurring losses, negative cash flows, and dependence on external funding.
• There is no assurance that the company will be able to secure additional financing through equity or debt offerings on acceptable terms.
• The company is in the early stages of product development, with no FDA approval granted for any products, and no guarantee of future approval or successful commercialization.
• Continued issuance of common stock for cash, debt, and compensation leads to significant shareholder dilution.
• Prominent related-party transactions, including loans from the CEO and revenue/notes with Zander Therapeutics (under common control), could pose conflicts of interest or impact financial stability.
• Disclosure controls and procedures were deemed ineffective, raising concerns about the reliability of financial reporting.
• Realization of deferred tax assets from net operating loss carryforwards is uncertain and subject to limitations, such as ownership changes.

Future Outlook

Management intends to secure additional operating funds through equity or debt offerings to support ongoing operations and development plans. The company plans to continue developing regenerative medical applications up to Phase I and/or Phase II clinical trials, with a specific focus on a planned Phase I Clinical Trial for HemaXellerate. There is no assurance that the company will be able to sell or license any product or that such sales/licenses will be on favorable terms.

Management Comments

• "Management intends to secure additional operating funds through equity or debt offerings."
• "The Company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations."
• "Without additional funding, there is substantial doubt about the Company's ability to continue as a going concern for the twelve months from the date of these financial statements."
• David Koos, Principal Executive Officer and Principal Financial Officer, concluded that the company's disclosure controls and procedures were ineffective as of the period covered.

Industry Context

StockSavvy.ai notes that the biopharma industry, particularly in regenerative medicine and oncology, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles (e.g., FDA approval). Companies in early development stages, like Regen Biopharma, often rely heavily on external financing and face substantial cash burn. The company's focus on NR2F6 inhibition/expression for oncology and autoimmune diseases places it in a competitive and high-risk segment. The reliance on related-party transactions and the explicit 'going concern' warning are red flags that differentiate it from more established or well-funded industry peers.

Comparison to Industry Standards

• Regen Biopharma's cash balance of $4,578 is critically low, significantly below industry standards for a development-stage biopharma company. Many small-cap biotechs typically maintain cash reserves in the tens of millions to fund ongoing R&D and operational expenses for at least 12-18 months.
• The net cash used in operating activities of $197,941 for the quarter, while not exceptionally high in absolute terms for the industry, is unsustainable given the minimal cash reserves. Companies like Moderna or BioNTech, even in their early stages, had much larger cash positions to support their R&D pipelines.
• The company's revenue of $59,065, primarily from licensing agreements, is negligible for a publicly traded biopharma, indicating it is far from commercialization. Successful development-stage biotechs often have larger upfront payments or milestone revenues from partnerships.
• The $210,000 R&D expense for the quarter is very modest for a company pursuing clinical trials. A typical Phase I clinical trial can cost several million dollars, and a Phase II trial significantly more. For example, companies like Gilead Sciences or Amgen spend billions annually on R&D. Even smaller, clinical-stage biotechs often report R&D expenses in the millions per quarter.
• The explicit 'going concern' warning is a severe indicator of financial distress, common among highly speculative early-stage companies but a significant deviation from financially stable industry players.
• The continuous issuance of common shares for cash and debt conversion, leading to a massive increase in weighted average shares outstanding (from 4.1 million to 99.6 million year-over-year), is a common but aggressive financing strategy for distressed biotechs, far exceeding the dilution rates of more robust companies.

Corporate Governance

Related Party Transactions

• Accounts receivable from a related party totaled $232,298 as of December 31, 2025, where the CEO is also an executive of the related company.
• Revenue of $27,425 was recognized from Zander Therapeutics, Inc., which is under common control with the company and whose CEO/Chairman is also the company's CEO.
• Notes payable to David Koos, the company's CEO, amounted to $73,303, bearing 15% simple interest per annum and due on demand.
• Notes payable to Zander Therapeutics, Inc. totaled $59,200, bearing 10% simple interest per annum with various maturity dates in 2025.
• The sublease of office space from BST Partners (controlled by David Koos) was terminated on December 1, 2025; the company now utilizes office space provided by the CEO free of charge.
• David Koos, the company's Chairman and CEO, received 20 million newly issued common shares as compensation for services related to the planned Phase I Clinical Trial of HemaXellerate, subject to a vesting schedule.

Stakeholder Impact

• Shareholders face significant dilution from the continuous issuance of common stock for cash, debt satisfaction, and compensation, potentially eroding per-share value.
• Creditors, particularly holders of convertible notes, face increased risk regarding repayment or conversion terms given the company's severe financial distress and 'going concern' warning.
• Employees and consultants receiving stock-based compensation (e.g., Dr. Lander, David Koos) have their compensation tied to the highly uncertain future performance and viability of the company.
• Existing licensees (Zander Therapeutics, Oncology Pharma) may face risks if the company's financial instability hinders its ability to sustain operations or advance its intellectual property.

Next Steps

• Secure additional operating funds through equity or debt offerings to support working capital requirements and business plans.
• Continue development of regenerative medical applications, including actively identifying small molecules for oncology and autoimmune disease applications.
• Advance the planned Phase I Clinical Trial of HemaXellerate.
• Evaluate for uncertain tax positions in the future.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by an explicit 'going concern' warning, critically low cash reserves ($4,578), escalating net and operating losses, and a growing accumulated deficit. The heavy reliance on dilutive equity financing and convertible debt, coupled with ineffective disclosure controls, presents substantial and immediate risks to investors. While there is R&D activity, the funding is insufficient for meaningful clinical trial progress, making the stock highly speculative with significant downside risk and a high probability of further value erosion.

Keywords

Biopharma, Regenerative Medicine, Oncology, Autoimmune Disease, HemaXellerate, Phase I Clinical Trial, SEC 10-Q, Going Concern, Convertible Debt, Equity Financing, Share Dilution, Related Party Transactions, Financial Reporting, Drug Development